CARsgen Therapeutics Holdings Limited announced that CARsgen has initiated patient enrollment for Phase 2 of the clinical trial for CT041 in the U.S. for the treatment of CLDN18.2 positive advanced gastric cancer/gastroesophageal junction cancer (GC/GEJ) in patients who have failed at least 2 prior lines of systemic therapies.